Ludwig Enterprises Inc (LUDG) Kazanmak

Ludwig Enterprises Inc, operates as a biotech and healthcare holding company. The company is headquartered in Pompano Beach, Florida. The company went IPO on 2007-12-11. Its proprietary mRNA genomic technology has the potential of screening for genetic biomarkers for inflammatory-driven diseases, including, but not limited to, heart disease, diabetes, preeclampsia, cancer and long COVID. The firm employs a non-invasive cheek swab test to collect mRNA samples. Its initial product candidate is the Revealia Breast test, a non-invasive cheek swab assay designed to detect molecular signatures in mRNA expression associated with the presence of breast cancer. Its technology platform integrates three key components: non-invasive sample collection, genomic analysis, and machine learning-based interpretation.